SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on May 2, 2017, covering events occurring on April 26, 27, and 29, 2017. The filing details the execution and initial closing of a Securities Purchase Agreement and a subsequent Registration Rights Agreement.
Key Financial Metrics
- Capital Raised (Tranche 1): Approximately $3.5 million (1,346,154 shares).
- Share Price: $2.60 per share.
- Total Potential Raise: Up to $25.0 million across three tranches.
- Remaining Tranches: Approximately $16.4 million and $5.1 million pending.
- Liquidity/Debt: The filing does not provide specific data on total cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the issuance of unregistered common stock to accredited investors. On April 27, 2017, the first tranche of the equity offering closed. The shares were sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. Additionally, a Registration Rights Agreement was executed on April 29, 2017, obligating the company to register the shares for resale.
Outlook, Risks, and Contingencies
- Registration Obligations: The Company must file registration statements for the resale of shares and use reasonable best efforts to have them declared effective within agreed timeframes.
- Liquidated Damages: If the Company fails to file or maintain effective registration statements, or fails to satisfy Rule 144 public information requirements, it must pay liquidated damages of 1.0% of the aggregate purchase price per month, capped at 5%.
- Investor Status: Purchasers represented they are accredited investors acquiring shares for investment purposes only.
Investor Verification Checklist
- Verify the closing status and proceeds of the remaining two tranches ($16.4 million and $5.1 million).
- Confirm the filing date and effectiveness status of the registration statement required under the Registration Rights Agreement.
- Review the full text of the Registration Rights Agreement (Exhibit 99.1) for specific timelines and conditions.
- Check subsequent filings for any liquidated damages payments or defaults related to the registration obligations.